^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR

    i
    Other names: 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR
    Associations

    News

    Trials
    Company:
    SZGIMI
    Drug class:
    CD20-targeted CAR-T immunotherapy, CD123-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy, CD10-targeted CAR-T immunotherapy, CD38-targeted CAR-T immunotherapy, TSLPR-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    20d
    CAR-T Immunotherapy Targeting CD19- ALL (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 --> Dec 2029 | Trial primary completion date: Jul 2021 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD38 (CD38 Molecule) • CRLF2 (Cytokine Receptor Like Factor 2) • CD22 (CD22 Molecule) • MME (Membrane Metalloendopeptidase) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR • 4SCAR-T